Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03188263 · ClinicalTrials.gov registry record · NA
Morning Light Treatment to Improve Glucose Metabolism
A NA study of PreDiabetes and Circadian Dysregulation, sponsored by Northwestern University.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT03188263: Completed NA study of PreDiabetes and Circadian Dysregulation, sponsored by Northwestern University.
NCT03188263 is a NA study of PreDiabetes and Circadian Dysregulation that has completed, run by Northwestern University. The registered enrollment target is 10 participants, below the 701-participant average among 149 other PreDiabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03188263, a NA study of PreDiabetes and Circadian Dysregulation, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this pilot study is to test a novel head worn light device (Re-Timer®) as an intervention to improve glucose metabolism in people with prediabetes. The hypothesis is that morning light treatment will improve glucose metabolism. This is a pilot study and the data from this project will be used to develop a larger clinical trial.
Primary Outcome
The OGTT is a 3-hour procedure measuring blood glucose levels after the patient has consumed a 75-gram dextrose solution at -15 min, 0 min, 30 min, 60 min, 90 min, 120 min, and 180 min intervals. Total area-under-the-curve of glucose levels is calculated.
Conditions Studied
Interventions
- OTHER Bright Light
- OTHER Dim Light
Study Locations (1)
Illinois
- Northwestern Memorial Hospital - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-09-05 |
| Est. Completion | 2019-12-31 |
| Phase | NA |
What the finished NCT03188263 record still lists
NCT03188263 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 701-participant average among 149 other PreDiabetes trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with PreDiabetes appearing as the primary indexed condition, and to 2 interventions - of which Bright Light is the first listed.
NCT03188263 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT03188263 about?
NCT03188263 is a clinical study titled "Morning Light Treatment to Improve Glucose Metabolism". The primary purpose of this pilot study is to test a novel head worn light device (Re-Timer®) as an intervention to improve glucose metabolism in people with prediabetes. The hypothesis is that morning light treatment will improve glucose metabolism. This is a pilot study and the data from this proj...
What is the current status of trial NCT03188263?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2017-09-05. Estimated completion is 2019-12-31.
What conditions does trial NCT03188263 study?
This clinical trial studies the following conditions: PreDiabetes, Circadian Dysregulation.
What interventions are being tested in trial NCT03188263?
The interventions under investigation include: Bright Light (OTHER), Dim Light (OTHER).
Who is sponsoring clinical trial NCT03188263?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03188263 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PreDiabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03188263's enrollment target sits among peer trials
10 148th of 149 higher than 2 of 149 other PreDiabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other PreDiabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Black Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention
RECRUITING · NA
-
Diabetes Clinical Decision Support
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA
-
Cleaner Air for Lower Cardiometabolic Risk
RECRUITING · NA
-
Strategies for Implementing a Postpartum Lifestyle Intervention in WIC Clinics
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI